| Supplier |
Creative Peptides |
| Product # |
10-101-109 |
| CAS # |
154-68-7 |
| Pricing |
Inquire
|
| Synonyms |
2-(N-Phenyl-N-benzyl-aminomethyl)imidazoline . phosphate; 2-[(N-Benzylanilino)methyl]-2-imidazoline . phosphate; 4,5-Dihydro-N-phenyl-N-(phenylmethyl)-1H-imidazole-2-methanamine . phosphate
|
| MolecularFormula |
C17H22N3O4P
|
| MolecularWeight |
265.36 (net), 363.35 (phosphate)
|
| ShippingCondition |
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
|
| Explanation |
Antazoline Phosphate, as phosphate salt of antazoline, is the histamine H1 receptor antagonist. It acts as an antihistamine. Generally by combinating with a decongestant, antazoline phosphate is applied topically to relieve the symptoms of allergic conjunctivitis.
|
| ChemicalName |
N-benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline;phosphoric acid
|
| Application |
Conjunctivitis
|
| Activity |
Antagonist
|
| InChI |
InChI=1S/C17H19N3.H3O4P/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16;1-5(2,3)4/h1-10H,11-14H2,(H,18,19);(H3,1,2,3,4)
|
| InChIKey |
DUIGUKRYYAGJAF-UHFFFAOYSA-N
|
| CanonicalSMILES |
C1CN=C(N1)CN(CC2=CC=CC=C2)C3=CC=CC=C3.OP(=O)(O)O
|
| Solubility |
Soluble in DMSO, not in water
|
| Appearance |
Solid powder
|
| Target |
Histamine H1 receptor
|
| Reference |
- A controlled, double-blind comparison of naphalzoline hydrochloride 0.05%, antazoline phosphate 0.5%, a combination of both components and a placebo was performed on 51 ragweed sensitive patients presenting allergic conjunctivitis. Evaluation of response at various times after instillation of medication for lacrimation, conjunctival inflammation, pruritus, photophobia and pain showed naphazoline hydrochloride, antazoline phosphate and the combination product superior to placebo. The combination product was statistically significantly superior for conjunctival inflammation and photophobia. The need for post-challenge treatment with epinephrine hydrochloride was significantly less in those eyes treated with the combination product. demonstrating prophylactic efficacy.
- Miller J, Wolf E H. Antazoline phosphate and naphazoline hydrochloride, singly and in combination for the treatment of allergic conjunctivitis-a controlled, double-blind clinical trial[J]. Annals of allergy, 1975, 35(2): 81-86.
- A method for the determination of 2-[(N-phenyl)benzylaminomethyl]-2-imidazoline X H3PO4 (antazoline phosphate) and 2-(1,2,3,4-tetrahydro-1-naphthyl)-2-imidazoline X HCl (tetrahydrozoline hydrochloride) in ophthalmic solution is described. The pharmaceutical preparation is analysed directly by reversed-phase ion-pair high-performance liquid chromatography and the method is very rapid, selective and simple.
- Puglisi G, Sciuto S, Chillemi R, et al. Simultaneous high-performance liquid chromatographic determination of antazoline phosphate and tetrahydrozoline hydrochloride in ophthalmic solution[J]. Journal of Chromatography A, 1986, 369: 165-170.
|
| Purity |
>98% (or refer to the Certificate of Analysis)
|
| AreasOfInterest |
Neurological Disease
|
| ShortTermStorageConditions |
Dry, dark and at 0 - 4 °C
|
| LongTermStorageConditions |
-20 °C
|
| Format |
neat
|
| LabelingTarget |
Histamine Receptor
|
| BoilingPoint |
235-236 °C(lit.)
|
| MeltingPoint |
120-122ºC
|